title: Radiosensitivity and TP 53, EGFR amplification and LOH10 analysis of primary glioma cell cultures.
abstract: OBJECTIVE
  Determination of in-vitro radiosensitivity and genetic alterations of cell cultures derived from human glioma biopsy tissue and established glioma cell lines.
  
  
  METHODS
  Fresh brain tumor specimens of six patients were processed to early passage cell cultures. In addition the cell lines D 384 and Gli 6 were used. Cell cultures were irradiated with doses from 2 to 10 Gy. Following irradiation, cell survival was determined by clonogenic assay and survival curves were generated. The surviving fractions after 2 Gy (SF2) and 4 Gy (SF4) were used as radiosensitivity parameters. Genetic analysis included determination of the mutational and loss of heterozygosity (LOH) status of TP 53 (exons 5-8), the LOH 10- and epidermal growth factor receptor gene (EGFR) amplification status.
  
  
  RESULTS
  The SF2 and SF4 values ranged from 0.54 to 0.88 (mean: 0.70) and from 0.13 to 0.52 (mean: 0.32), respectively. Genetic alterations were found in the Gli 6 cell line and in two primary cell cultures. The genetic profile of Gli 6 showed LOH but no TP 53 mutation, complete LOH 10 and no EGFR amplification. The VU 15 cell culture showed TP 53 mutation but no LOH 10 or EGFR amplification, while VU 24 showed incomplete LOH 10, EGFR amplification and no TP 53 mutation. In the other four cell cultures and D 384 cell line no genetic alterations were diagnosed. Histopathological classification of glioblastoma multiforme and/or genetic alterations resulted in lower radiosensitivity.
  
  
  CONCLUSIONS
  In this small series of early passage glioma cell cultures low radiosensitivity and alterations in cell regulatory genes were seen. Further testing of biological behavior in larger series of patient-derived material is ongoing.
authors.affiliation: Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands. gerlach@med.uni-duesseldorf.de
authors.forename: Bärbel
authors.initials: B
authors.lastname: Gerlach
authors.forename: Anna H
authors.initials: AH
authors.lastname: Harder
authors.forename: Theo J M
authors.initials: TJ
authors.lastname: Hulsebos
authors.forename: Sieger
authors.initials: S
authors.lastname: Leenstra
authors.forename: Berend J
authors.initials: BJ
authors.lastname: Slotman
authors.forename: W Peter
authors.initials: WP
authors.lastname: Vandertop
authors.forename: Karl-Axel
authors.initials: KA
authors.lastname: Hartmann
authors.forename: Peter
authors.initials: P
authors.lastname: Sminia
mesh_terms: D000328:Adult; D000368:Aged; D015139:Blotting, Southern; D001932:Brain Neoplasms / Q000235:genetics / Q000532:radiotherapy* / Q000601:surgery; D002470:Cell Survival / Q000528:radiation effects; D005260:Female; D005500:Follow-Up Studies; D005784:Gene Amplification; D018773:Genes, erbB-1; D016158:Genes, p53; D005909:Glioblastoma / Q000235:genetics / Q000532:radiotherapy; D005910:Glioma / Q000235:genetics* / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D019656:Loss of Heterozygosity; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016133:Polymerase Chain Reaction; D011829:Radiation Dosage; D011836:Radiation Tolerance; D014407:Tumor Cells, Cultured / Q000528:radiation effects